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ABSTRACT
Background. There is an ongoing debate about expanding
the resection criteria for hepatocellular carcinoma (HCC)
beyond the Barcelona Clinic Liver Cancer (BCLC)
guidelines. We sought to determine the factors that held the
most prognostic weight in the pre- and postoperative set-
ting for each BCLC stage by applying a machine learning
method.
Methods. Patients who underwent resection for BCLC-0,
A and B HCC between 2000 and 2017 were identified from
an international multi-institutional database. A Classifica-
tion and Regression Tree (CART) model was used to
generate homogeneous groups of patients relative to
overall survival (OS) based on pre- and postoperative
factors.
Results. Among 976 patients, 63 (6.5%) had BCLC-0, 745
(76.3%) had BCLC-A, and 168 (17.2%) had BCLC-B
HCC. Five-year OS among BCLC-0/A and BCLC-B
patients was 64.2% versus 50.2%, respectively (p = 0.011).
The preoperative CART model selected a-fetoprotein
(AFP) and Charlson comorbidity score (CCS) as the first
and second most important preoperative factors of OS
among BCLC-0/A patients, whereas radiologic tumor
burden score (TBS) was the best predictor of OS among
BCLC-B patients. The postoperative CART model
revealed lymphovascular invasion as the best postoperative
predictor of OS among BCLC-0/A patients, whereas TBS
remained the best predictor of long-term outcomes among
BCLC-B patients in the postoperative setting. On multi-
variable analysis, pathologic TBS independently predicted
worse OS among BCLC-0/A (hazard ratio [HR] 1.04, 95%
confidence interval [CI] 1.02–1.07) and BCLC-B patients
(HR 1.13, 95% CI 1.06–1.19) undergoing resection.
Conclusion. Prognostic stratification of patients undergo-
ing resection for HCC within and beyond the BCLC
resection criteria should include assessment of AFP and
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comorbidities for BCLC-0/A patients, as well as tumor
burden for BCLC-B patients.
Hepatocellular carcinoma (HCC) ranks as the fifth most
common cancer worldwide and is considered the most
rapidly increasing cause of cancer-related deaths in the
US.1,2 Accurate preoperative staging is critical to define the
prognosis of patients with HCC and inform treatment
recommendations.3,4 Among the staging systems available,
the Barcelona Clinic Liver Cancer (BCLC) classification
has been largely adopted and routinely used by physicians
in the West.5–7 According to the BCLC system, liver
resection should be offered only to patients with very early
(i.e. BCLC-0) or early (i.e. BCLC-A) stage HCC, whereas
patients with intermediate and advanced HCC (i.e. BCLC-
B and BCLC-C) should be referred for non-surgical man-
agement, including transarterial chemoembolization
(TACE) and sorafenib, respectively.6,7
Advances in surgical techniques, radiologic assessment,
and perioperative management have increased the
resectability rates of HCC worldwide. Indeed, more than
60% of patients diagnosed with HCC are currently offered
surgery in Asia, whereas the corresponding rates in the
West range from 25 to 40%.8,9 Of note, a growing number
of patients currently undergo surgery for HCC beyond the
BCLC criteria, with acceptable reported outcomes.8 For
example, Wada et al. reported a 5-year overall survival
(OS) of 63.4% among 85 patients with multinodular
BCLC-B HCC undergoing liver resection.10 In a separate
study, a select group of patients with BCLC-B or -C HCC
had improved long-term outcomes following resection
versus locoregional therapy or best supportive care.11
Nevertheless, while benefitting certain individuals, surgery
does not provide a benefit to all patients. In turn, surgeons
need to weigh the benefits of operating on patients beyond
the current BCLC criteria against the possible risks asso-
ciated with more extensive liver resection.
Given the ongoing debate around expanding the resec-
tion criteria for HCC, defining the most important
clinicopathologic factors relative to long-term outcomes is
important to help construct a tailored therapeutic strategy
based on individual patient characteristics. As such, the
objective of the current study was to identify the factors
most predictive of survival prior to and following resection
of HCC within and beyond the BCLC guidelines. Specifi-
cally, we sought to determine the factors that held the most
prognostic weight in the pre- and postoperative setting for
each BCLC stage by applying a machine learning method
on a large multi-institutional cohort of patients who
underwent curative-intent resection of HCC.
METHODS
Study Population and Data Collection
Patients who underwent resection for HCC between
2000 and 2017 were identified from an international multi-
institutional database. Patients were treated at 1 of 11
participating institutions: The Ohio State University Wex-
ner Medical Center, Columbus, OH, USA; Yokohama City
University School of Medicine, Yokohama, Japan;
University of Verona, Verona, Italy; Ospedale San Raf-
faele, Milan, Italy; Curry Cabral Hospital, Lisbon,
Portugal; APHP, Beaujon Hospital, Clichy, France; West-
mead Hospital, Sydney, NSW Australia; Stanford
University, Stanford, CA, USA; Fundeni Clinical Institute,
Bucharest, Romania; University of Ottawa, Ottawa, ON,
Canada; and The University of Sydney, School of Medi-
cine, Sydney, NSW, Australia. Patients were followed and
outcomes were recorded in a prospectively maintained
multi-institutional database. Patients with BCLC stages 0,
A and B HCC6 were included in the final cohort. Patients
who (1) had BCLC-C tumors, (2) did not receive curative
intent resection, (3) did not have data on pathologic as well
as radiologic tumor size and number, and, finally (4) did
not have adequate follow-up data were excluded from the
analysis. The study was approved by the Institutional
Review Boards of all participating institutions.
Demographic and clinical data included age, sex,
American Society of Anesthesiologists (ASA) score,
Charlson Comorbidity Index (CCI) score, history of cir-
rhosis, hepatitis B virus (HBV)/hepatitis C virus (HCV)
infection, laboratory values (i.e. platelet count, albumin,
total bilirubin, aspartate aminotransferase [AST], alanine
aminotransferase [ALT], international normalized ratio
[INR], a-fetoprotein [AFP]), Child–Pugh class, BCLC
stage, minimally invasive surgery, type of surgical resec-
tion (i.e. minor or major), tumor size and grade, pathologic
lymphovascular invasion, liver capsule involvement, mar-
gin status (i.e. R0, R1, R2), as well as radiologic and
pathologic tumor burden score (TBS).
Definitions
According to the latest European Association for the
Study of Liver (EASL) guidelines, BCLC-0 was defined as
a single tumor\ 2 cm; BCLC-A was defined as a single
tumor C 2 cm or two to three nodules, all\ 3 cm; and
BCLC-B was defined as two to three nodules C 3 cm or
four or more nodules. 6 In case of multiple nodules, tumor
size was calculated on the basis of largest lesion size.
Major hepatectomy was defined as resection of three or
more Couinaud segments,12 and TBS was defined as the
distance from the origin of a Cartesian plane, and
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comprised of two variables: maximum tumor size (x-axis)
and number of tumors (y-axis), so that TBS2 = (maximum
tumor diameter)2 ? (number of tumors)2, as previously
described.13 Pathologic TBS for each patient was calcu-
lated based on final pathologic reports, while radiologic
TBS was calculated based on the information obtained
from preoperative computed tomography scans.
Statistical Analysis
Descriptive statistics were presented as median (in-
terquartile range [IQR]) and frequency (%) for continuous
and categorical variables, respectively. OS was defined as
the time interval between the date of hepatectomy and the
date of death. For patients who remained alive, OS was
censored at the date of last follow-up. Recurrence-free
survival (RFS) was defined as the time interval between
hepatectomy and date of recurrence. Bivariate survival
analyses were performed using the log-rank test and pre-
sented using Kaplan–Meier curves. Variables that were
significant on bivariate analysis (p\ 0.05) and did not
violate the proportional hazards assumptions were entered
into the multivariable Cox regression model. A backward
step selection method was used to eliminate non-significant
variables using a p value\ 0.10. The level of statistical
significance for all tests was set at a = 0.05. All statistical
analyses were performed using SPSS version 25 (IBM
Corporation, Armonk, NY, USA).
Classification and Regression Tree (CART) Model
A Classification and Regression Tree (CART) model
was used to generate homogeneous groups of patients
relative to OS based on pre- (preoperative CART model)
and postoperative (preoperative CART model) factors.
CART is a class of nonparametric risk prediction models
that performs a recursive partition of the ‘covariate space’,
as previously described.14 Survival regression trees are able
to create an easy-to-interpret prediction model that identi-
fies the optimal cut-off values and stratifies patients into
different groups relative to survival.14 The ‘goodness of fit’
method was used to maximize between-node separation,
and the log-rank statistic was used to measure between-
node heterogeneity. The optimal cut-off was based on best
split among the variable using the highest log-rank statistic.
To prune the tree and to minimize overfitting, the lowest
complexity parameter was used with the one minus stan-
dard error rule that reflected the trade-off between the tree
complexity and how well the tree fit the data. To assess the
predictive performance of the final model, the concordance
index (c-index) for time-to-event data was calculated with
the bootstrapping resample method (n = 2000) using the R
CRAN package Hmisc. The CART model was developed
using the R CRAN software for statistical computing ver-
sion 3.6.0 with the additional packages: survival, partykit,
rpart, Hmisc, caret and ROCR.
RESULTS
Baseline Characteristics in the Entire Cohort
Among 976 patients with HCC included in the final
analytic cohort, 6.5% (n = 63) of patients had BCLC-0,
76.3% (n = 745) had BCLC-A, and 17.2% (n = 168) had
BCLC-B HCC (Table 1). Median patient age was 67 years
(IQR 59–74), most patients were male (n = 748 , 76.7%),
had an ASA score B 2 (n = 570, 63.1%), and a Charlson
comorbidity score (CCS) B 4 (n = 489, 54.2%). History of
cirrhosis and HBV and HCV infection were present in
38.9% (n = 379), 27.6% (n = 267) and 31.3% (n = 303) of
patients, respectively. The vast majority of patients had
AFP B 400 ng/mL (n = 694, 80.5%) and Child–Pugh class
A liver function (n = 699, 95.2%). Approximately one-
quarter of patients underwent minimally invasive surgery
(n = 237, 24.4%) and approximately one-third had a major
resection (n = 334, 35.1%). Median tumor size was 5 cm
(IQR 3.0–8.5) and most tumors were well-to-moderately
differentiated (n = 753, 79.9%). Median pathologic TBS
was 5.1 cm (IQR 3.4–8.8), and radiologic TBS was com-
parable (median 5.1 cm [IQR 3.3–8.5]). Following
resection, lymphovascular invasion and liver capsule
involvement were present in 39.2% (n = 346) and 32.8%
(n = 240) of tumor specimens, respectively. The vast
majority of patients had an R0 resection (n = 825, 86.8%).
Preoperative CART Model: Selection of Patients
for Resection Within and Beyond the Barcelona Clinic
Liver Cancer (BCLC) Guidelines
CART analysis revealed that AFP levels, CCS, and
radiologic TBS were the best preoperative prognostic fac-
tors associated with OS among BCLC-0/A and BCLC-B
patients undergoing resection (Fig. 1). Of note, 5-year OS
among BCLC-0/A and BCLC-B patients undergoing
resection was 64.2% versus 50.2% (p = 0.011), respec-
tively (electronic supplementary Fig. 1). Five-year RFS
among patients undergoing resection for BCLC-0/A and
BCLC-B HCC was 36.9% versus 24.5%, respectively
(p\ 0.001). Among BCLC-0/A patients, CART selected
AFP and CCS as the first and second most important pre-
operative factors associated with OS. Specifically, patients
with lower AFP levels and CCS B 4 had a 5-year OS as
high as 75%, whereas patients with the highest AFP levels
had only a 5-year OS of 23.6%. Of note, among BCLC-B
patients, only radiologic TBS was selected by the CART
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algorithm as being the best predictor of OS. Specifically,
patients with radiologic TBS\ 7.87 had a 5-year OS of
60.5% versus only 28.9% among patients with TBS[ 7.87
(Fig. 1). The model performed well in both the training (c-
index 0.641) and validation datasets with bootstrapping
resamples (c-index 0.604).
Postoperative CART Model: Factors Associated
with Overall Survival (OS) Following Resection
The postoperative CART model revealed lymphovas-
cular invasion as the best postoperative predictor of OS
among BCLC-0/A patients, followed by preoperative AFP
levels, ASA class, and CCS. In contrast, among BCLC-B
patients, pathologic TBS remained the best predictor of
long-term outcomes (Fig. 2). Among BCLC-0/A patients,
5-year OS was 54.6% versus 70% for individuals who did
TABLE 1 Demographics and patient characteristics in the entire
cohort (N = 976)
Variable Value





B 2 570 (63.1)
[ 2 334 (36.9)
Charlson comorbidity score
B 4 489 (54.2)










Platelet count, 9 103/lL
B 150 284 (30.5)
[ 150 648 (69.5)
Albumin, g/dL
B 3.5 177 (22.8)
[ 3.5 601 (77.2)
Total bilirubin, mg/dL
B 1.2 760 (84.3)
[ 1.2 142 (15.7)
AST, U/L
B 40 391 (44.4)
[ 40 490 (55.6)
ALT, U/L
B 56 591 (64.6)
[ 56 324 (35.4)
PT/INR
B 1.1 709 (77.5)
[ 1.1 206 (22.5)
AFP, ng/mL
B 400 694 (80.5)




















Well to moderate 753 (79.9)











Pathologic TBS 5.1 (3.4–8.8)
Radiologic TBS 5.1 (3.3–8.5)
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, ASA-PS American Society of Anesthesiolo-
gists performance score, HBV hepatitis B virus, HCV hepatitis C
virus, AST aspartate aminotransferase, ALT alanine aminotransferase,
AFP a-fetoprotein, PT/INR prothrombin time/international normal-
ized ratio, BCLC Barcelona Clinic Liver Cancer, TBS tumor burden
score







































































































































g75.0% 64.8% 52.2% 23.6% 60.5% 28.9%
FIG. 1 A CART model depicting the hierarchical association of preoperative factors relative to 5-year overall survival stratified by BCLC stage.
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FIG. 2 A CART model depicting the hierarchical association of
postoperative factors relative to 5-year overall survival stratified by
BCLC stage. CART Classification and Regression Tree, BCLC
Barcelona Clinic Liver Cancer, ASA American Society of
Anesthesiologists, TBS tumor burden score
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and did not have lymphovascular invasion on pathology,
respectively (p\ 0.001) [electronic supplementary Fig-
ure 2]. Among individuals with lymphovascular invasion,
individuals with the lowest AFP levels (B 16 ng/mL)
achieved a 5-year OS as high as 73.9%, whereas among
patients with higher AFP levels ([ 16 ng/mL), 5-year OS
ranged from 41.7% to 63.9% depending on the preopera-
tive ASA class. Among patients without lymphovascular
invasion on pathology, individuals with CCS B 4 had a
5-year OS as high as 73.9%, whereas patients with
CCS[ 4 had a 5-year OS of 60.3%. Of note, among
BCLC-B patients, individuals with pathologic TBS B 11
had a 5-year OS of 60.1% versus only 13.9% among
patients with TBS[ 11. The prognostic model performed
well in both the training (c-index 0.661) and internal
bootstrapping validation (c-index 0.634) datasets.
After a median follow-up of 26.5 months (IQR
12.5–51.1), 369 (45.7%) and 105 (62.5%) patients had a
recurrence following resection of BCLC 0/A and BCLC-B
HCC, respectively. Of note, treatment modalities following
recurrence were comparable among BCLC-0/A and BCLC
B patients (BCLC-0/A vs. BCLC B, repeat hepatectomy:
44/336 [13.1%] vs. 9/104 [8.7%]; local ablation: 110/336
[32.7%] vs. 37/104 [35.6%]; transarterial embolization/
TACE: 92/336 [27.4%] vs. 31/104 [29.8%]; sorafenib or
other supportive therapy: 90/336 [n = 26.8%] vs. 27/104
[26.0%]; p = 0.64).
Multivariable Analysis of OS
Several factors were associated with prognosis following
resection for BCLC-0/A and BCLC-B HCC (electronic
supplementary Table 1). On multivariable analysis, after
adjusting for competing risk factors, age[ 65 years (hazard
ratio [HR] 1.36, 95% confidence interval [CI] 1.03–1.80;
p = 0.03), CCS[ 4 (HR 1.77, 95% CI 1.33–2.34;
p\ 0.001), AFP[ 400 ng/mL (HR 1.41, 95% CI
1.03–1.94; p = 0.033), lymphovascular involvement (HR
1.70, 95% CI 1.26–2.29; p\ 0.001), R1/R2 resection (HR
1.54, 95% CI 1.03–2.29; p = 0.036), and pathologic TBS
(HR 1.04, 95% CI 1.02–1.07; p = 0.001) were independent
predictors of OS among BCLC-0/A patients. In contrast,
only poor/undifferentiated tumor grade (HR 2.43, 95% CI
1.37–4.30; p = 0.002) and pathologic TBS (HR 1.13, 95%
CI 1.06–1.19; p\ 0.001) independently predicted worse OS
among BCLC-B patients undergoing resection (Table 2).
DISCUSSION
Over the last three decades, the incidence of HCC has
been steadily increasing in both Eastern and Western
countries with a concomitant increase in HCC
mortality.1,15 Accurate preoperative staging is critical to
define the prognosis of patients with HCC and inform
treatment recommendations.3,4 Among the traditional
staging systems, the BCLC classification—largely adopted
by physicians in the West—not only assesses patient
prognosis but also assigns treatment allocation based on
prognostic subclasses.5,6 Although endorsed by the EASL
and the American Association for the Study of Liver Dis-
ease (AASLD),5–7 this system has recently been questioned
relative to the proposed treatment allocation. Indeed, a
number of investigators have reported favorable outcomes
following resection beyond the current criteria (i.e. BCLC-
B or even BCLC-C HCC). Nevertheless, there is currently
no consensus as to which patients will benefit the most
from surgery. As such, stratifying patients into distinct
prognostic groups within each BCLC stage has been a topic
of debate. The current study was important because we
utilized a CART machine-based learning model to identify
the most predictive factors relative to long-term survival
among patients undergoing resection within (i.e. BCLC-0/
A) and beyond (i.e. BCLC-B) the current BCLC resection
criteria. Using this technique, we were able to define six
prognostic groups of patients based on factors demon-
strated to be the most predictive of OS. Of note, AFP and
CCS dominated prognosis for BCLC-0/A patients (within
BCLC), whereas radiologic TBS predicted OS the most for
BCLC-B patients (beyond BCLC). TBS was consistently
identified as the most important prognostic factor among
BCLC-B patients, either pre- (radiologic TBS) or postop-
eratively (pathologic TBS). In contrast, lymphovascular
invasion, followed by AFP, CCS, and ASA class mostly
determined OS in the postoperative setting for BCLC-0/A
patients. In addition, 5-year OS ranged from 23.6% to 75%
among different BCLC-0/A subgroups, whereas BCLC-B
subgroups had a 5-year OS ranging from 28.9% to 60.5%.
To the best of our knowledge, this is the first study in the
literature to utilize a machine learning method as a means
to identify different prognostic groups within BCLC stages
in the pre- and postoperative setting.
Several investigators have suggested that the BCLC
classification may be an oversimplification of how physi-
cians treat HCC patients. Indeed, a number of studies have
demonstrated heterogeneous outcomes after resection of
HCC, even within the same BCLC stage.11,16 To this point,
our own group reported different outcomes among patients
within the BCLC-A stage that were largely dependent on
tumor size.17 Indeed, patients with single large tumors
([ 5 cm) had a 5-year OS of 56.9%, which was markedly
lower than the OS among patients with smaller size solitary
tumors (5-year OS: 69%), yet comparable with patients
who underwent surgery for BCLC-B HCC (5-year OS:
49.9%; p = 0.259).17 In addition, Wada and colleagues
reported a distinct prognosis for patients undergoing
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resection for multinodular (BCLC-B) HCC, thus high-
lighting the need for further subclassification of BCLC
stages, especially BCLC-B tumors.10 Ruan et al. recently
proposed a nomogram based on total tumor volume, Child–
Pugh class, plasma fibrinogen levels, and the presence of
portal vein thrombosis to predict OS prior to resection for
HCC beyond BCLC-A stage.18 The authors suggested three
groups of patients (i.e. low, medium, and high risk) with
the lowest risk group having a 5-year OS and RFS similar
to that of the BCLC-A patients (5-year OS: 83.1% vs.
83.1%, p = 0.46; 5-year RFS: 50.6% vs. 55.9%,
p = 0.68).18 The current study revealed that TBS was
associated with OS in both BCLC-0/A and BCLC-B
patients, even after adjusting for competing risk factors. Of
note, for each point increase in TBS, the hazards of death
increased by 4% among BCLC-0/A patients, whereas the
corresponding increase was 13% among BCLC-B patients
(Table 2). These data were consistent with a recent study
by the ITA.LI.CA group that demonstrated a 6% increased
risk of death for each point increase in TBS.13,19 Of note, in
the current study, both pre- and postoperative CART
models demonstrated that both radiologic and pathologic
TBS were the most important indicators of long-term
outcomes among BCLC-B patients undergoing resection
for HCC. Importantly, surgery may offer patients with a
radiologic TBS B 7.8 an acceptable 5-year OS (60.5%),
which was even better than that of certain groups of
patients presenting with BCLC-0/A tumors (Fig. 1). As
such, by calculating radiologic TBS, clinicians could pre-
operatively identify patients with tumors beyond the
current BCLC resection guidelines who are most likely to
derive the most benefit from surgery. In addition, patho-
logic TBS should be considered an important predictor of
survival following resection for HCC beyond the current
BCLC resection guidelines.
Recently, an increasing number of studies have
reported acceptable outcomes following resection for
BCLC-B HCC, suggesting that liver resection may be
justified in select patients beyond the BCLC resection
criteria.20–22 A recent study reported a 5-year OS of
63.4% following liver resection for multinodular BCLC-
B HCC.10 Furthermore, in a propensity-matched cohort,
Kim et al. reported superior outcomes for patients with
BCLC-B who were treated with resection versus non-
surgical treatment (5-year OS: 63% vs. 22%).20 In
addition, a recent meta-analysis demonstrated a survival
TABLE 2 Multivariable analysis of survivala
Variable BCLC-0/A BCLC-B
HR 95% CI p value HR 95% CI p value
Age, years
B 65 Ref
[ 65 1.36 1.03–1.80 0.03 –
CCS
B 4 Ref
[ 4 1.77 1.33–2.34 \0.001 –
AFP, ng/mL
B 400 Ref
[ 400 1.41 1.03–1.94 0.033 –
Grade
Well/moderate Ref Ref
Poor/undifferentiated 1.33 0.98–1.81 0.069 2.43 1.37–4.30 0.002
Lymphovascular involvement
No Ref –
Yes 1.70 1.26–2.29 \ 0.001
Margin
R0 Ref Ref
R1/R2 1.54 1.03–2.29 0.036 1.70 0.92–3.16 0.093
Pathologic TBS 1.04 1.02–1.07 0.001 1.13 1.06–1.19 \0.001
CCS Charlson comorbidity score, AFP a-fetoprotein, BCLC Barcelona Clinic Liver Cancer, TBS tumor burden score, HR hazard ratio, CI
confidence interval, Ref reference
aThe final step of the backward stepwise model is presented for both BCLC-0/A and B stages
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benefit for surgery compared with TACE among BCLC-
B patients, thus questioning the treatment algorithm
proposed by the current BCLC classification schema.22
By analyzing a large multi-institutional database, we
herein reported a 5-year OS of 50.2% among BCLC-B
patients. Interestingly, BCLC-B patients with radiologic
TBS B 7.87 had a 5-year OS as high as 60.5%, which
was even higher than the OS of BCLC-A patients with
extremely high AFP (5-year OS: 23.6%) or AFP[ 55
ng/mL, and CCS[ 4 (5-year OS: 52.2%). As such, the
current study suggests that surgery may indeed be ben-
eficial in select patients with BCLC-B HCC, especially
when TBS is low.
The present study should be interpreted in the light of
certain limitations. The retrospective nature of the study
may have introduced a selection bias as to which patients
were offered surgery (i.e. patients with BCLC-B HCC
possibly had more favorable tumor biology). In addition,
the vast majority of patients included in the study had
favorable liver function (i.e. Child–Pugh class A), and thus
the findings may not pertain to patients with more severe
underlying liver disease. Furthermore, the current study did
not include patients with BCLC-C tumors. As such, future
studies should aim to verify the results in these patient
populations. Although prophylactic treatment after surgery
may be beneficial in certain circumstances (i.e. presence of
microvascular invasion, tumor size[ 5 cm),23,24 this
information was not available in the current dataset,
although the overall use of prophylactic treatment was
presumably very low. Finally, although the machine
learning techniques, such as the CART models, improve
our ability to preoperatively predict patient prognosis,
incorporation of genetic and molecular profiles of HCC
will be necessary to further optimize the predictive ability
of these models.
CONCLUSIONS
Surgery provided acceptable outcomes among select
patients with BCLC-B HCC. While AFP and CCS
appeared to be the best prognostic factors associated with
survival among BCLC-0/A patients, a machine-based
CART model identified TBS (either radiologic or patho-
logic) as the best predictor of outcomes among BCLC-B
patients undergoing resection. These data further empha-
size the need for refinement of the proposed BCLC
treatment algorithm and advocate for the use of TBS for
risk stratification and prognostic estimation among patients
presenting with HCC beyond the current resection criteria.
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